The Role of Platelet to Lymphocyte Ratio (PLR) in Predicting Early Treatment Response in Diffuse Large B Cell Lymphoma

IF 0.9 4区医学 Indian Journal of Hematology and Blood Transfusion Pub Date : 2024-08-12 DOI:10.1007/s12288-024-01839-2

Kadir Ilkkilic, Bayram Sen, Osman Cure

{"title":"The Role of Platelet to Lymphocyte Ratio (PLR) in Predicting Early Treatment Response in Diffuse Large B Cell Lymphoma","authors":"Kadir Ilkkilic, Bayram Sen, Osman Cure","doi":"10.1007/s12288-024-01839-2","DOIUrl":null,"url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Background</h3><p>Systemic inflammatory response in diffuse large B-cell lymphoma (DLBCL) is closely related to disease prognosis. Our aim is to determine the role of pretreatment platelet-to-lymphocyte ratio (PLR) in predicting early treatment response in DLBCL patients.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>This retrospective study included 94 patients. The correlation of PLR at the time of diagnosis with early treatment response was evaluated.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>66 patients responded to treatment and 28 patients were unresponsive or partially responsive. In univariate analysis, age, eastern cooperative oncology group performance status (ECOG-PS), disease stage, extranodal involvement, neutrophil-to-lymphocyte ratio (NLR), PLR, hemoglobin, albumin, lymphocyte, platelet (HALP) score were found to predict response to treatment. Multivariate analysis revealed that PLR and ECOG-PS were independent predictors of early treatment response.</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>PLR can be used by clinicians as an effective, inexpensive inflammatory parameter supplementary to the IPI score to predict early treatment response to chemoimmunotherapy. Treatment of patients with DLBCL with high PLR at the time of diagnosis with more potent regimens may be a rational approach for patients to benefit more from treatment.</p>","PeriodicalId":13314,"journal":{"name":"Indian Journal of Hematology and Blood Transfusion","volume":null,"pages":null},"PeriodicalIF":0.9000,"publicationDate":"2024-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian Journal of Hematology and Blood Transfusion","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12288-024-01839-2","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Systemic inflammatory response in diffuse large B-cell lymphoma (DLBCL) is closely related to disease prognosis. Our aim is to determine the role of pretreatment platelet-to-lymphocyte ratio (PLR) in predicting early treatment response in DLBCL patients.

Methods

This retrospective study included 94 patients. The correlation of PLR at the time of diagnosis with early treatment response was evaluated.

Results

66 patients responded to treatment and 28 patients were unresponsive or partially responsive. In univariate analysis, age, eastern cooperative oncology group performance status (ECOG-PS), disease stage, extranodal involvement, neutrophil-to-lymphocyte ratio (NLR), PLR, hemoglobin, albumin, lymphocyte, platelet (HALP) score were found to predict response to treatment. Multivariate analysis revealed that PLR and ECOG-PS were independent predictors of early treatment response.

Conclusion

PLR can be used by clinicians as an effective, inexpensive inflammatory parameter supplementary to the IPI score to predict early treatment response to chemoimmunotherapy. Treatment of patients with DLBCL with high PLR at the time of diagnosis with more potent regimens may be a rational approach for patients to benefit more from treatment.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

血小板与淋巴细胞比值 (PLR) 在预测弥漫大 B 细胞淋巴瘤早期治疗反应中的作用

背景弥漫大B细胞淋巴瘤（DLBCL）的系统性炎症反应与疾病预后密切相关。我们的目的是确定治疗前血小板淋巴细胞比值（PLR）在预测 DLBCL 患者早期治疗反应中的作用。结果66例患者对治疗有反应，28例患者无反应或部分有反应。在单变量分析中，年龄、东部合作肿瘤学组表现状态（ECOG-PS）、疾病分期、结节外受累、中性粒细胞与淋巴细胞比值（NLR）、PLR、血红蛋白、白蛋白、淋巴细胞、血小板（HALP）评分可预测治疗反应。多变量分析显示，PLR和ECOG-PS是早期治疗反应的独立预测因子。结论临床医生可将PLR作为一种有效、廉价的炎症参数，作为IPI评分的补充，预测化疗免疫疗法的早期治疗反应。对于诊断时PLR较高的DLBCL患者，采用更有效的治疗方案可能是使患者从治疗中获益更多的合理方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Indian Journal of Hematology and Blood Transfusion Medicine-Hematology

自引率

0.00%

发文量

期刊介绍： Indian Journal of Hematology and Blood Transfusion is a medium for propagating and exchanging ideas within the medical community. It publishes peer-reviewed articles on a variety of aspects of clinical hematology, laboratory hematology and hemato-oncology. The journal exists to encourage scientific investigation in the study of blood in health and in disease; to promote and foster the exchange and diffusion of knowledge relating to blood and blood-forming tissues; and to provide a forum for discussion of hematological subjects on a national scale. The Journal is the official publication of The Indian Society of Hematology & Blood Transfusion.